Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

October 3, 2018

Primary Completion Date

February 18, 2019

Study Completion Date

February 18, 2019

Conditions

Acute Myeloid Leukemia (AML)Minimal Residual Disease

Interventions

DRUG

Azacitidine

AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1

DRUG

Avelumab

Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT

Trial Locations (1)

Memorial Sloan Kettering Cancer Center, New York